Related Experiment Video

Updated: Jun 6, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions

John M S Bartlett1

  • 1Endocrine Cancer Group and Edinburgh Breakthrough Breast Cancer Laboratory, Edinburgh University,Western General Hospital, Crewe Road South, Edinburgh, UK. john.bartlett@ed.ac.uk

Clinical Breast Cancer
|December 1, 2010
PubMed

Insights

Dysregulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway drives aggressive breast cancer. Biomarker development is crucial for validating new targeted therapies and improving patient selection for treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is critical in cellular functions.
  • Aberrant PI3K/Akt/mTOR signaling is implicated in breast cancer pathogenesis, contributing to aggressive disease and therapeutic resistance.
  • Genetic and epigenetic alterations frequently dysregulate this pathway in breast cancer.

Purpose of the Study:

  • To review current advancements in understanding PI3K/Akt/mTOR pathway alterations in breast cancer.
  • To highlight key molecular changes affecting response to targeted therapies.
  • To identify knowledge gaps and propose future research directions for biomarker development.

Main Methods:

  • Literature review of genetic and molecular alterations in the PI3K/Akt/mTOR pathway in breast cancer.
  • Analysis of current therapeutic strategies targeting this pathway.
  • Synthesis of information on biomarker development and patient stratification.

Main Results:

  • Numerous molecular alterations (mutations, amplifications, deletions, methylation) dysregulate the PI3K/Akt/mTOR pathway in breast cancer.
  • Novel therapeutic agents targeting this pathway are under development.
  • Biomarker-driven patient selection is essential for the success of these novel agents.

Conclusions:

  • Understanding PI3K/Akt/mTOR pathway alterations is key to developing effective breast cancer treatments.
  • Further research is needed to facilitate biomarker development for targeted therapies.
  • Collaborative efforts in drug and biomarker development are essential for clinical translation.

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...